Mystic Holdings (MSTH) Fair Value & Analysis
Healthcare · US · Market cap $1.3M
Mystic Holdings
MSTH · US
Fair value as of: Jun 26, 2026
From 6 valuation models · updated 7 days ago
Fair value updated Jun 26, 2026 — revised from $0.0600 to $0.0011 (−98.2%) since Jun 24, 2026. Share price −90.0% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.0011 – $0.0500 · the $0.0011 price screens below the $0.0011 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Mystic Holdings (MSTH) currently trades at $0.0011, while our model-based Fair Value estimate is $0.0011 — implying the stock looks roughly 0.2% undervalued today. We read business quality at 42/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Mystic Holdings generated revenue of $21.4M at a net margin of -29.9%. Revenue grew 18.9% year over year. It earns a return on equity of -35.2%. Net debt stands at $10.3M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Mystic Holdings, Inc., through its subsidiaries, engages in the cultivation and production of medical and recreational cannabis in the United States. It offers cannabis flowers; edibles, such as gummies, brownie bites, cookies, caramels, rice crispies, and chocolate chip bars; concentrates and oils; pre-rolls and small bud batches; and cannabis vape products under the Qualcan, Lush, and Cosmic brands. The company also operates recreational/medical retail dispensaries; and provides branding consulting services for third-party cannabis products. It serves state-licensed dispensaries. The company was founded in 2014 and is based in Las Vegas, Nevada.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
Mystic Holdings reported revenue of $21.4M in FY2024 versus $13.4M in FY2020, a compound +12.5%/yr. Reported net income was −$6.4M in FY2024.
Is MSTH fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Swedish Orphan Biovitrum AB SOBI | kr 444.80 | kr 440.64 | -1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Mystic Holdings (MSTH) undervalued?
What is the fair value of MSTH?
What is the quality score of MSTH?
What is the revenue of Mystic Holdings (MSTH)?
What is the net profit margin of MSTH?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.